Drug reference

Oxerutins

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 269

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Relief of symptoms of oedema associated with chronic venous insufficiency ▶BY MOUTH ▶Adult: 500 mg twice daily

PDF page 269

Safety

Side Effects

▶Rare or very rare Alopecia. arthralgia. diarrhoea. dizziness. fatigue. ﬂushing. gastrointestinal discomfort. gastrointestinal disorders. headache. photosensitivity reaction. skin reactions Cardiovascular system l LESS SUITABLE FOR PRESCRIBING Oxerutins (rutosides) are not vasodilators and are not generally regarded as effective preparations as capillary sealants or for the treatment of cramps; they are less suitable for prescribing.

PDF page 269

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Capsule ▶Paroven (GlaxoSmithKline Consumer Healthcare) Oxerutins 250 mg Paroven 250mg capsules | 120 capsule p £27.07 DT = £27.07 VASODILATORS › PERIPHERAL VASODILATORS

PDF page 269

Dose text by age group

Adult

500 mg twice daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 269

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Oxerutins

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 269

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Relief of symptoms of oedema associated with chronic venous insufficiency ▶BY MOUTH ▶Adult: 500 mg twice daily

PDF page 269

Safety

Side Effects

PDF page 269

Dose and formulations

Medicinal Forms

PDF page 269

Dose text by age group

Adult

500 mg twice daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 269

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.